Antitumoral effect of IL-12 gene transfected via liposomes into B16F0 cells

• Authors: Lucía Speroni , Julieta Gasparri , Victoria de los A Bustuoabad , Nadia S Chiaramoni , Andrzej Smagur , Stanisław Szala , María C Taira , Silvia del V Alonso
• Languages of publication: EN

Abstracts

EN

Murine melanoma B16F0 cells were transfected with SA:DPPC:DOPE (2:1:1 molar ratio) liposomes associated with a plasmid encoding murine IL-12. Stearylamine, a cationic lipid, showed a greater transfection efficiency compared to DOTAP-containing liposomes. The lipid:DNA ratio was 2:1 (w/w). Control groups were mock transfected or transfected with an empty plasmid (pNeo). pNeo or IL-12 transfected cells and controls were inoculated intradermically into the dorsal region of the foot or the lateral flank of C57BL6 mice. Results showed that IL-12 expression had a marked effect on in vivo growth of B16 melanoma tumors developed in both anatomic sites, significantly retarding their growth and prolonging host survival.

Keywords

EN

stearylamine; liposomes; B16F0 cells; B16 melanoma; IL-12

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2009
• Volume: 56
• Issue: 2
• Pages: 249-253

Dates

published

2009

received

2008-12-19

revised

2009-04-15

accepted

2009-04-27

(unknown)

2009-05-07

Contributors

author

Lucía Speroni

• Laboratorio de Biomembranas, Departamento de Ciencia y Tecnologia, Universidad Nacional de Quilmes, Buenos Aires, Argentina

author

Julieta Gasparri

• Laboratorio de Biomembranas, Departamento de Ciencia y Tecnologia, Universidad Nacional de Quilmes, Buenos Aires, Argentina

author

Victoria de los A Bustuoabad

• Instituto de la Visión; Hospital Oftalmológico Malvinas Argentinas; Buenos Aires, Argentina, Buenos Aires, Argentina

author

Nadia S Chiaramoni

• Laboratorio de Biomembranas, Departamento de Ciencia y Tecnologia, Universidad Nacional de Quilmes, Buenos Aires, Argentina

author

Andrzej Smagur

• Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

author

Stanisław Szala

• Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

author

María C Taira

• Laboratorio de Biomembranas, Departamento de Ciencia y Tecnologia, Universidad Nacional de Quilmes, Buenos Aires, Argentina

author

Silvia del V Alonso

• Laboratorio de Biomembranas, Departamento de Ciencia y Tecnologia, Universidad Nacional de Quilmes, Buenos Aires, Argentina

References

• Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J, Mazda O (2002) Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin 12 and IL-18 by means of the EBV/lipoplex. Mol Ther 5: 609-616.
• Attia MA, Weiss DW (1966) Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain-A mice infected with mammary tumor virus. Cancer Res 26: 1787-1800.
• Bangham AD (1972) Model membranes. Chem Phys Lipids 8: 386-392.
• Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230.
• Budryk M, Wilczyńska U, Szary J, Szala S (2000) Direct transfer of IL-12 gene into growing Renca tumors. Acta Biochim Polon 47: 385-391.
• Colombo MP, Trinchieri G (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168.
• Elzaouk L, Moelling K, Pavlovic J (2006) Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 15: 865-874.
• Fu J, Zheng J, Fang W (1998) Interleukin-12 gene transfection into murine B16 melanoma cells suppresses tumorigenicity and decreases metastatic potential. Zhonghua Yi Xue Za Zhi 78: 627-629.
• Jacobsen F, Mertens-Rill J, Beller J, Hirsch T, Daigeler A, Langer S, Lehnhardt M, Steinau HU, Steinstraesser L (2006) Nucleofection: a new method for cutaneous gene transfer? J Biomed Biotechnol Article ID 26060, 2006: 1-8.
• Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, Ito M, Yagita H, Okumura K (1999) Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 29: 1390-1396.
• Lasek W, Basak G, Switaj T, Jakubowska AB, Wysocki PJ, Mackiewicz A, Drela N, Jalili A, Kamiński R, Kozar K, Jakóbisiak M (2004) Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol Immunother 53: 363-372.
• Nanni P, Rossi I, De Giovanni C, Landuzzi L, Nicoletti G, Stoppacciaro A, Parenza M, Colombo MP, Lollini PL (1998) Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res 58: 1225-1230.
• Prehn R (2007) Immunostimulation and immunoinhibition of premalignant lesions. Theor Biol Med Model 4: 6.
• Son K, Patel D, Tkach D, Park A (2000) Cationic liposome and plasmid DNA complexes formed in serum-free medium under optimum transfection condition are negatively charged. Biochim Biophys Acta 1466: 11-15.
• Smyth MJ, Taniguchi M, Street SE (2000) The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 165: 2665-2670.
• Switaj T, Jalili A, Jakubowska AB, Drela N, Stoksik M, Nowis D, Basak G, Golab J, Wysocki PJ, Mackiewicz A, Sasor A, Socha K, Jakóbisiak M, Lasek W (2004) CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin Cancer Res 10: 4165-4175.
• Wang D, Jing N, Lin Q (1996) Stearylamine liposome as a new efficient reagent for dna transfection of eukaryotic cells. Biochem Biophys Res Commun 226: 450-455.
• Wang JC, Liu XY, Lü WL, Lee HS, Goh BC, Zhang Q (2005) The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes. Yao Xue Xue Bao 40: 475-480.